Clinical trials · Philadelphia, PA
Chronic Inflammatory Demyelinating Polyneuropathy clinical trials in Philadelphia
We’re tracking 8 recruiting chronic inflammatory demyelinating polyneuropathy studies with a site in or near Philadelphia — including Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Philadelphia
- NCT06798012RecruitingPhase 2
TAK-411 for adults with CIDP
This study tests a new investigational drug called TAK-411 for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for people who have already responded to immunoglobulin therapy and are on a stable dose.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07091630RecruitingPhase 3
A study of empasiprubart for chronic inflammatory demyelinating polyneuropathy (CIDP)
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06920004RecruitingPhase 3
Testing empasiprubart vs IVIg for chronic CIDP
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07032662RecruitingPhase 2
Testing Imeroprubart for adults with CIDP
This trial tests a new drug called Imeroprubart for people with CIDP who are already on a stable treatment like steroids or immunoglobulin. The goal is to see if the drug can help control symptoms better.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06859099Enrolling by invitationPhase 3
Long-term safety study of Riliprubart for CIDP
This study checks the long-term safety and how well riliprubart works for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for those who have already taken riliprubart in a previous study.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03684018RecruitingPhase 4
Testing two doses of Privigen for children with CIDP
This study tests whether two different dose levels of Privigen (a type of immune blood treatment) are safe and effective for children and teens with CIDP. It may help improve nerve-related symptoms in people whose CIDP has been confirmed or is being evaluated as likely.
Philadelphia, PennsylvaniaAges 2–17 - NCT04929236RecruitingPhase 3
Testing different PANZYGA doses for children with CIDP
This Phase 3 study compares different dose schedules of PANZYGA (immune-globulin) in children with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It aims to find a dosing plan that is both safe and effective for improving symptoms and function.
Philadelphia, PennsylvaniaAges 2–17 - NCT06290141RecruitingPhase 3
Testing riliprubart vs. standard IVIg for CIDP
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Chronic Inflammatory Demyelinating Polyneuropathy trial opens near Philadelphia, PA
We’ll email you when one opens near Philadelphia, PA — at most once a week, no account needed, unsubscribe anytime.
Chronic Inflammatory Demyelinating Polyneuropathy trials in other cities
Where these studies are running near Philadelphia
Institutions with a site for the recruiting chronic inflammatory demyelinating polyneuropathy studies listed above.
- Jefferson Health Honickman Center · 2 studies
- Penn Therapeutics CRS · 2 studies
- University of Pennsylvania · 2 studies
- Children's Hospital of Philadelphia
- Octapharma Research Site
- Perelman Center for Advanced Medicine
- Site Number - 1616
What taking part in a chronic inflammatory demyelinating polyneuropathy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting chronic inflammatory demyelinating polyneuropathy studies in Pennsylvania.
Common questions
- Are there chronic inflammatory demyelinating polyneuropathy clinical trials near Philadelphia?
- Yes. We're currently tracking 8 recruiting chronic inflammatory demyelinating polyneuropathy studies with a site near Philadelphia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic inflammatory demyelinating polyneuropathy study near Philadelphia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Philadelphia to take part?
- Not necessarily. These studies have a site near Philadelphia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic inflammatory demyelinating polyneuropathy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic inflammatory demyelinating polyneuropathy studies open near Philadelphia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.